AAIC 2025 Abstract
Real‐World Insights on the Lecanemab Patient Pathway in Early Alzheimer’s Disease in the United States
By Michael Henry Rosenbloom, Marwan N. Sabbagh, Jose A. Soria-Lopez, Show 10 more authorsDaryl Jones
Study in peoplePopulations
Abstract
Background: Lecanemab‐irmb (LEQEMBI®) is indicated for the treatment of patients with Alzheimer’s disease (AD) in the mild cognitive impairment or mild dementia stage. The optimized patient pathway enables early and accurate diagnosis of AD and supports patients and care partners through initiation of treatment and appropriate monitoring.
